Skip to main content
OpenTrials
Completed

NCT Number: NCT05615870

Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters

This is a multi-center, parallel, double-blind, randomized controlled clinical trial. Children <12 months of age hospitalized with bronchiolitis are randomized 1:1 to receive a 24-week home intervention with filtration units containing HEPA and carbon filters (in the child's sleep space and a common room) to improve indoor air quality (IAQ) or to a control group with filtration units without HEPA and carbon filters. The HEPA intervention units and control units will be used for 24 weeks after pre-intervention IAQ measurements. Children are followed for respiratory outcomes over the pre-intervention and intervention periods.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 week–12 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alaska Native Tribal Health Consortium, Anchorage, Alaska, United States

Loading trial locations.

About this study

This is a multi-center, parallel, double-blind, randomized controlled clinical trial. Two hundred twenty-eight children <12 months old with their first hospitalization for bronchiolitis will be randomized 1:1 (stratified by site) to receive 24 weeks of home intervention with active HEPA filtration units to improve IAQ or to a control group without a HEPA or carbon filter inside identical-appearing units. Children will be followed for respiratory symptoms during a pre-intervention period of up to two weeks following randomization and during an intervention period of 24 weeks.

This study is designed to reduce barriers to participation for rural participants in that there will be no required study visits to a distant study site, and all study activities and data collection will be conducted remotely. Participants will be identified in hospitals in ISPCTN states, maximizing the chances that rural and medically underserved populations are represented. It is common for rural children with bronchiolitis to be transferred to tertiary care centers in urban/suburban locales, so inclusion of urban hospitals will allow for recruitment of this population.1 It is important for rural children to be represented in a bronchiolitis study in order to increase generalizability. Rural and underserved children have a higher risk of decreased access to medical care for symptoms and illness episodes, and a higher burden of asthma.83,84 These families may have air pollutant exposure profiles distinct from those residing in urban areas. For example, they might experience less exposure to traffic-related pollutants but may have more wood stove use or exposure to agricultural pollutants or wildfires. With its diversity of sites, the ECHO ISPCTN is well-positioned to enroll rural children that might otherwise be excluded.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age <12 months at hospital admission
  • First-time hospitalization for bronchiolitis
  • One primary residence (>5 days per week)
  • Parent, legal guardian or other legally authorized representative consents to allow their child to participate and agrees to participate in all study activities
  • Electricity in the home (required to power the study equipment)
  • Wireless internet access or cellular service access in the home*
  • English or Spanish-speaking parent or guardian

Exclusion criteria

  • Chronic airway or respiratory conditions requiring home oxygen, mechanical ventilation, or tracheostomy dependence; known immunodeficiency, hemodynamically significant cardiac conditions including those requiring medication or oxygen; cystic fibrosis; neuromuscular disease; eligible for palivizumab (per AAP guidelines87)
  • Use of stand-alone home HEPA filtration other than study-related HEPA units in the home
  • Household member who smokes (any type), vapes, or uses e-cigarettes
  • Intention to move in the next 6 months
  • Enrolled or plans to enroll in an interventional clinical trial for treatment of acute bronchiolitis or sequelae of bronchiolitis, unless permission given by the PI
  • Another child in the household is enrolled in this study (one child per household can enroll)

Treatment and study plan

Winix 5500-2 HEPA filtration units

Other

To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared to a use of a control unit.

Primary outcomes

  1. Number of Caregiver-reported Symptom-free Days (SFDs)

    Time frame: 24 Weeks

    An SFD is defined as a 24-hour period without coughing, wheezing, or trouble breathing

Secondary outcomes

  1. Number of Hospitalizations, Emergency Department or Urgent Care Visits or Other Unscheduled Medical Visits for Respiratory Complaints

    Time frame: 24 weeks

    Caregiver reported number of hospitalizations, emergency department or urgent care visits, other unscheduled medical visits, and the sum of total counts of all metrics for respiratory complaints

  2. Total Quality of Life (QOL) Score

    Time frame: 24 weeks

    QOL score is measured by the Pediatric Quality of Life Inventory TM (PedsQLTM) Infants Scales questionnaire. The scores are reverse-scored and linearly transformed to a 0-100 scale. Higher scores mean a better outcome.

  3. Average Particulate Matter (PM2.5) Levels

    Time frame: 24 weeks

    PM2.5 levels (Particulate Matter ≤ 2.5 micrometers in diameter) are measured by in-home monitors and scaled to unit of micrograms per cubic meter per week. Higher levels mean a worse outcome.

Sponsors and collaborators

Lead sponsor

IDeA States Pediatric Clinical Trials Network

Network

Collaborators

  • National Institutes of Health (NIH)
  • University of Montana
  • University of Vermont Medical Center

Registry information

Acronym: BREATHE

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 14, 2022
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.